The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Costs and Effectiveness of Routine Therapy with Long-Term Beta-Adrenergic Antagonists after Acute Myocardial Infarction
Abstract
We analyzed the costs and effectiveness of routine therapy with beta-adrenergic antagonists in patients who survived an acute myocardial infarction. On the basis of data pooled from the literature, this form of therapy resulted in a 25 percent relative reduction annually in the mortality rate for years 1 to 3 and a 7 percent relative reduction for years 4 to 6 after a myocardial infarction. The estimated cost of six years of routine beta-adrenergic-antagonist therapy to save an additional year of life was $23,400 in low-risk patients, $5,900 in medium-risk patients, and $3,600 in high-risk patients, assuming that the entire benefit of earlier treatment is lost immediately after six years. Under a more likely assumption--that the benefit of six years of treatment wears off gradually over the subsequent nine years--the estimated cost of therapy per year of life saved would be $13,000 in low-risk patients, $3,600 in medium-risk patients, and $2,400 in high-risk patients. As compared with coronary-artery bypass grafting and the medical treatment of hypertension, routine beta-adrenergic-antagonist therapy has a relatively favorable cost-effectiveness ratio.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Cited by
Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
Epstein, F. H., Lipton, S. A., & Rosenberg, P. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300907 · Cited by 2,658
Task Force on Sudden Cardiac Death of the European Society of Cardiology
Priori, S. (2001) · European Heart Journal · doi:10.1053/euhj.2001.2824 · Cited by 903
Gunnar, R. M., Bourdillon, P. D., Dixon, D. W., Fuster, V, Karp, R. B., Kennedy, J. W., Klocke, F. J., Passamani, E. R., Pitt, B., & Rapaport, E. (1990) · Circulation · doi:10.1161/01.cir.82.2.664 · Cited by 474
Cost-Effectiveness of Detecting and Treating Diabetic Retinopathy
Javitt, J. C., & Aiello, L. P. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-1_part_2-199601011-00017 · Cited by 411
Handling uncertainty when performing economic evaluation of healthcare interventions.
Briggs, & Gray (1999) · Health Technology Assessment · doi:10.3310/hta3020 · Cited by 387
Metadata
- Authors
- Goldman, L., Sia, S. T. B., Cook, E. F., Rutherford, J. D., & Weinstein, M. C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1988-07-21
- Volume
- 319
- Issue
- 3
- Pages
- 152-157
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2336613424
- Cited by
- 197
- References
- 1
- FWCI
- 41.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Costs and Effectiveness of Routine Therapy with Long-Term Beta-Adrenergic Antagonists after Acute Myocardial Infarction. https://app.cochat.ai/papers/10.1056/nejm198807213190306
- The paper
- Goldman, L., Sia, S. T. B., Cook, E. F., Rutherford, J. D., & Weinstein, M. C. (1988). Costs and Effectiveness of Routine Therapy with Long-Term Beta-Adrenergic Antagonists after Acute Myocardial Infarction. New England Journal of Medicine. https://doi.org/10.1056/nejm198807213190306
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.